EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population

Lindsay Somerville iD, Larry Borish, Imre Noth, Dana Albon iD

Therapeutic Advances in Respiratory Disease · 2024-01 · 18

DOI: 10.1177/17534666241297877 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 14.11.2024. Verfasst von Lindsay Somerville und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Virginia, 1215 Lee Street, Charlottesville, VA 2908, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) causes life-shortening respiratory and systemic disease due to dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. Highly effective modulator therapies (HEMT) improve the lives of many people with cystic fibrosis (PwCF) by correcting the structure and function of the defective CFTR channel at the molecular level. Despite these advancements, a subset of patients—termed modulator-refractory CF—continues to experience two or more pulmonary exacerbations per year requiring hospitalization or intravenous antibiotics, regardless of other modulator benefits. This underrecognized group represents an emerging challenge within the CF community. We discuss the benefits and limitations of current CFTR modulator therapies and the urgent need to investigate this emerging at-risk population. While HEMT improves lung function, decreases exacerbations, reduces the need for lung transplantation, and lowers mortality, increasing evidence shows that not all patients benefit equally. At the University of Virginia, nearly 6% of adults with CF exhibit the modulator-refractory phenotype. The driving factors of modulator-refractory CF are likely multifactorial, including genetic variations, variable immune responses, preexisting bronchiectasis, microbiological colonization, preexisting comorbid conditions, and environmental and socioeconomic factors. This perspective review recognizes and defines modulator-refractory CF as a distinct emerging clinical phenotype in the post-modulator era. Understanding this phenotype is crucial for reducing morbidity and mortality, and for improving the quality of life for PwCF. Raising awareness of modulator-refractory CF will help the community address this population and perform further research to identify causes. The emergence of modulator-refractory CF highlights a significant gap in our current treatment landscape and provides an opportunity to develop innovative therapeutic strategies that may benefit the entire CF community, ensuring that no person with CF is left behind.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansRisk FactorsLung TransplantationLungPhenotypeAnti-Bacterial AgentsDisease ProgressionTreatment OutcomeAdultDrug Resistance

Stichwörter der Autor:innen

cystic fibrosishighly-effective modulator therapymodulat0r-refractory cystic fibrosis

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, humanAnti-Bacterial Agents

Autor:innen und Institutionen

  • University of Virginia, 1215 Lee Street, Charlottesville, VA 2908, USA.
  • University of Virginia, Charlottesville, VA, USA.

ORCID-Profile: Lindsay Somerville, Dana Albon

Zitieren

APA

Somerville, L., Borish, L., Noth, I., & Albon, D. (2024). Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population. Therapeutic Advances in Respiratory Disease, 18. https://doi.org/10.1177/17534666241297877

Vancouver

Somerville L, Borish L, Noth I, Albon D. Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population. Therapeutic Advances in Respiratory Disease. 2024;18. doi:10.1177/17534666241297877

BibTeX
@article{Somerville2024,
  author = {Somerville, Lindsay and Borish, Larry and Noth, Imre and Albon, Dana},
  title = {Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2024},
  volume = {18},
  doi = {10.1177/17534666241297877}
}
Kostenlos starten →